Skip to content
Today is the last chance to vote for the Pantheon Awards, sponsored by the state of California’s most impactful life sciences membership organization, California Life Sciences (CLS) to recognize “the state’s leaders from across the pharmaceutical, biotech and other allied industries.”
As CLS informed when opening the nominations for its 19th edition back in July, “this is the second year the Pantheon Award winners will be determined by a public voting campaign”.
To celebrate the diverse contributions of scientists in the life sciences sector, CLS is introducing new award categories this year that include:
- Academia & Research
- BioPharma
- Convergent Technologies: MedTech, Digital, & Diagnostics
- Elizabeth Schar Inspiring Future Leaders Award
- Emerging Innovation
- Leadership
- Synthetic & Ag Bio
“We celebrate the innovative solutions and cutting-edge advancements being developed in laboratories, universities, and corporate and industry non-profits throughout our state. There is no better event for our sector to elevate and showcase those who are driving better patient outcomes,” said at the time Mike Guerra, CLS President, and CEO.
Several members of the Biotechnology Innovations Organization (BIO) are up for awards, including:
- BIO Board Members Paul Hastings (CEO of Nkarta Therapeutics) and Dr. Ted Love (CEO of Global Blood Therapeutics)
- Emily Leproust, CEO of Twist Bioscience and
- Day One Biopharmaceuticals and Travere Therapeutics, both nominated for the biopharma award, presented to the company that made the greatest advancement or contribution to the California life sciences sector the previous year.
Public voting which begun on October 3 and ends on October 14, will culminate on November 3 with the annual Pantheon Awards ceremony at the Westin St. Francis in San Francisco, the first one to take place in person since the COVID-19 pandemic.
